U.S. Representative Earl Blumenauer, known for his involvement in health policy, has raised concerns regarding the FDA’s oversight of Elon Musk’s Neuralink.
The lawmaker questioned why the FDA did not inspect the brain implant company before allowing it to conduct human trials.
Blumenauer’s inquiry stems from a report by Reuters revealing FDA inspectors’ findings of record-keeping and quality control issues at Neuralink’s facilities.
These findings occurred shortly after the startup obtained clearance to test its brain implants in humans. The concerns were related to animal experiments conducted by the company.
Related: First Neuralink Patient Makes ‘Full Recovery’ And ...